We came across a bullish thesis on Protagonist Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.’s share was trading at $85.64 as of December 1st. PTGX’s trailing and forward P/E were 128.19 and 26.39, respectively according to Yahoo Finance.
Pixabay/Public Domain
Protagonist Therapeutics (PTGX) represents a rare convergence of biotech innovation and pharmaceutical execution, built...
